Picture of AnaptysBio logo

ANABV — AnaptysBio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapHigh Flyer

AnaptysBio Inc expected to post a loss of 89 cents a share - Earnings Preview

* AnaptysBio Inc  ANAB.OQ   ANAB.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 9
(estimated) for the period ending June 30 2024
    * The San Diego California-based  company is expected to
report a
602.3% increase in revenue to $24.301 million from $3.46 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for AnaptysBio Inc is for a
loss
of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AnaptysBio
Inc is
$48.50​, above​ its last closing price of $32.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.56       -1.57      -1.59     Missed  -4.7
 Dec. 31 2024  -1.62                  -1.59             0.7
 Jun. 30 2023  -1.80       -1.79      -1.41     Beat    21.4​
 Jan. 1 0001   -1.83                  -1.50             11.6
 ​​Mar.        -1.08                  -1.58             
 31 2023                                                
 Dec. 31 2022  -0.96       -0.96      -1.18     Missed  2.8​
 Sep. 30 2022  -0.65       -0.72      -1.18     Missed  -63.1
 Jun. 30 2022  -0.89       -1.02      -1.15     Missed  -12.6
 This summary was machine generated August 3 at 02:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AnaptysBio

See all news